放出制御ドラッグデリバリーシステムの世界市場：薬物投与量、価格、臨床試験

近年、ドラッグデリバリーの範囲を多様化するため多大な努力が払われており、疾患の複雑な構成にも対応可能な放出制御ドラッグデリバリーシステムの実現に向けた取り組みが大きく前進しています。今では、感染症、炎症性疾患、自己免疫疾患、神経疾患、がんなどさまざまな患者集団に対応する経口、注射、経鼻、局所、埋め込み型の放出制御薬物が登場しており、医薬品市場で支配的な地位を確立しつつあります。

当レポートは、世界の放出制御ドラッグデリバリーシステムの市場を調査したもので、作用機序、原料ベースのアプローチ、パイプラインの概要、適応症別の分析、投与経路と処方についての考察、各種疾患に対応する医薬品についての分析、地域別のトレンド、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 ドラッグデリバリーについてのイントロダクション

• ドラッグデリバリーの概要
• ドラッグデリバリーシステム

第2章 放出制御ドラッグデリバリーシステムのイントロダクション

• 新たなドラッグデリバリーシステム
• 制御されたドラッグデリバリー
• 放出制御ドラッグデリバリーシステムの基礎

第3章 放出制御ドラッグデリバリーシステムの分類

• デリバリーシステム別
  • 即時薬物放出システム
  • 修正薬物放出システム
  • 遅延放出システム
  • 延長放出システム
  • 拍動性薬物放出システム
• 技術別
  • 事前プログラムされたドラッグデリバリーシステム
  • 活性化変調ドラッグデリバリーシステム
  • フィードバック調整ドラッグデリバリーシステム
  • 部位標的ドラッグデリバリーシステム
• 投与経路別
  • 経口
  • 経鼻
  • 経皮
  • 経眼
  • 非経口

第4章 作用機序

• 拡散制御
• 溶解制御システム
• 水浸透制御システム
• 侵食制御システム
• イオン交換制御システム

第5章 原料ベースのアプローチ

• ポリマー
• クロノファーマティクス
• ナノ粒子デリバリーシステム

第6章 臨床パイプラインの概要

• 段階
• 国/地域
• 作用機序
• 薬物クラス
• 適応症

第7章 適応症別市場

• 糖尿病
• 癌
• 心血管疾患
• 神経学的障害
• 感染症

第8章 投与経路と処方の考察

• 経腸投与製剤
  • 固形剤形
  • 液体剤形
  • 吸入剤形
• 非経口剤形
  • 注射剤形
  • 埋め込み型デバイス
• 薬物放出の一般的なメカニズム

第9章 アルツハイマー病の放出制御薬-価格、特許、投与量の考察

• Namzaric（拡張放出）
• Namenda XR（拡張放出）
• Razadyne ER（拡張放出）

第10章 パーキンソン病の放出制御薬-価格、特許、投与量の考察

• Gocovri（拡張放出）
• Osmolex ER（拡張放出）

第11章 統合失調症の放出制御薬-価格、特許、投与量の考察

• Perseris（拡張放出）
• Invega（拡張放出）
• Invega Sustenna / Invega Trinza（拡張放出）
• Seroquel XR （拡張放出）
• Abilify Maintena（拡張放出）
• Aristada （拡張放出）

第12章 慢性疼痛の放出制御薬-価格、特許、投与量の考察

• Zohydro ER（拡張放出）
• Hysingla ER（拡張放出）
• Nucynta ER（拡張放出）
• Kadian（拡張放出）
• Arymo ER（拡張放出）
• Xtampza ER（拡張放出）
• MS Contin（拡張放出）
• Embeda（拡張放出）

第13章 多発性硬化症の放出制御薬-価格、特許、投与量の考察

• Ampyra（拡張放出）
• Tecfidera（遅延放出）
• Rayos（遅延放出）
• Vumerity（遅延放出）

第14章 II型糖尿病の放出制御薬-価格、特許、投与量の考察

• Glumetza （拡張放出）
• Glucotrol XL（拡張放出）
• Fortamet（拡張放出）
• Glucophage XR （拡張放出）
• Bydureon（拡張放出）

第15章 高血圧と狭心症放出制御薬-価格、特許、投与量の考察

• Procardia XL （拡張放出）
• Toprol XL（拡張放出）
• Adalat CC（拡張放出）
• Verelan PM（拡張放出）
• Plendil（拡張放出）
• Cardizem LA（拡張放出）

第16章 臨床試験の考察

• 不明
• 研究
• 前臨床
• 臨床
• フェーズI
• フェーズI / II
• フェーズII
• フェーズII / III
• フェーズIII
• 事前登録
• 登録済み

第17章 企業別、適応症別の上市済み医薬品の臨床的考察

第18章 地域レベルの最新動向

• 米国
• 欧州
• 日本

第19章 市場の力学

• 市場成長要因
• 解決すべき課題

第20章 世界市場の将来展望

第21章 競合情勢

• Allergan
• Amylin Pharmaceuticals
• AstraZeneca
• BioAlliance Pharma
• Biogen
• Collegium Pharmaceutical
• Controlled Therapeutics (Ferring Pharmaceuticals)
• Cosmo Pharmaceuticals
• Egalet
• Elan Corporation
• Encore Therapeutics
• Flamel Technologies
• GlaxoSmithKline
• Heron Therapeutics
• iCeutica
• Mithra Pharmaceuticals
• Neurim Pharmaceuticals
• Novartis
• Orexigen Therapeutics
• Otsuka Pharmaceutical
• Pfizer
• Purdue Pharma
• Syntex Pharmaceuticals International
• Takeda
• Zealand Pharma

List of Figures

• Figure 1-1: Characteristics of an Ideal Drug Delivery System
• Figure 2-1: Limitations of the Conventional Drug Delivery Systems
• Figure 2-2: Diversification of the Novel Drug Delivery Platforms
• Figure 2-3: History of Drug Delivery Technology from First Generation till Third Generation
• Figure 2-4: Barriers to be Overcome by the Third Generation Drug Delivery System
• Figure 2-5: Demonstration of the Targeted & Non-Targeted Drug Delivery
• Figure 2-6: Controlled Drug Release is by Zero Order Mechanism
• Figure 3-1: Plasma Concentration v/s Time Profile in Conventional & Controlled Release
• Figure 3-2: Comparison of Varied Modified Drug Release Systems
• Figure 3-3: Illustration of Mechanism of Pulsatile Drug Release in Pulsincap
• Figure 3-4: Classification Based Over the Technicality Erudition
• Figure 3-5: Structural Differentiation among Varied Classified Drug Delivery Systems
• Figure 3-6: Classification Based over the Route of Administration
• Figure 4-1: Differentiation of the Two Forms of the Diffusion Controlled Mechanisms
• Figure 4-2: Mechanism of Encapsulation Dissolution Controlled System
• Figure 4-3: Osmotic Release of the Drug Delivery with the Controlled Mechanism
• Figure 4-4: Illustration of Erosion Mechanisms Found in Matrix Systems
• Figure 5-1: Categorization of Polymeric Controlled Drug Delivery Devices
• Figure 5-2: Varied Nanostructures Available for the Nanoparticulate Delivery System
• Figure 6-1: Global - Controlled Release Drug Clinical Pipeline by Phase (%), 2020 till 2026
• Figure 6-2: Global - Controlled Release Drug Clinical Pipeline by Phase (Number), 2020 till 2026
• Figure 6-3: Global - Controlled Release Drug Clinical Pipeline by Country/Region (Number), 2020 till 2026
• Figure 6-4: Global - Controlled Release Clinical Drug Pipeline by Mode of Action (Number), 2020 till 2026
• Figure 6-5: Global - Controlled Release Drug Clinical Pipeline by Drug Class (Number), 2020 till 2026
• Figure 6-6: Global - Controlled Release Drug Clinical Pipeline by indication (Number), 2020 till 2026
• Figure 7-1: Major Non-Invasive Administrative Routes of Insulin Delivery
• Figure 7-2: Layout of the Controlled Drug Delivery Approaches in Cancer Therapeutics
• Figure 7-3: Controlled Drug Delivery Approaches used to Deliver Drugs to CNS
• Figure 8-1: Dosage Formulations for the Controlled Drug Delivery
• Figure 8-2: Mechanism of the Controlled Drug Release of the Solid Dosage Forms
• Figure 8-3: Representation of Categories of Liquid Dosage Form
• Figure 8-4: Mechanism of Controlled Delivery of Parenteral Dosage Forms
• Figure 8-5: General Forms of Oral Controlled Release System Mechanism
• Figure 8-6: Schematic Diffusion Controlled Drug Release from Inert Matrices
• Figure 8-7: Demonstration of the Osmotic Pump Drug Release Mechanism
• Figure 9-1: Namzaric - Price of Oral Capsule, Extended Release of Dosage 10 mg-7 mg (US$), March' 2020
• Figure 9-2: Namzaric - Price of Oral Capsule, Extended Release of Dosage 10 mg-14 mg (US$), March' 2020
• Figure 9-3: Namzaric - Price of Oral Capsule, Extended Release of Dosage 10 mg-21 mg (US$), March' 2020
• Figure 9-4: Namzaric - Price of Oral Capsule, Extended Release of Dosage 10 mg-28 mg (US$), March' 2020
• Figure 9-5: Namenda XR - Available Dosage Strengths (mg), March' 2020
• Figure 9-6: Namenda XR - Price of Oral Capsules, Extended Release 7 mg (US$), March'2020
• Figure 9-7: Namenda XR - Price of Oral Capsules, Extended Release 14 mg (US$), March'2020
• Figure 9-8: Namenda XR - Price of Oral Capsules, Extended Release 21 mg (US$), March'2020
• Figure 9-9: Namenda XR - Price of Oral Capsules, Extended Release 28 mg (US$), March'2020
• Figure 9-10: Global - Namenda XR Quarterly Sales Q1 - Q4 (US$ Million), 2017 & 2018
• Figure 9-11: Razadyne ER - Available Dosage Strengths (mg), March' 2020
• Figure 9-12: Razadyne ER - Price of Oral Capsules, Extended Release 8 mg (US$), March' 2020
• Figure 9-13: Razadyne ER - Price of Oral Capsules, Extended Release 16 mg (US$), March' 2020
• Figure 9-14: Razadyne ER - Price of Oral Capsules, Extended Release 24 mg (US$), March' 2020
• Figure 10-1: Gocovri - Avaialable Dosage Strengths (mg)
• Figure 10-2: Gocovri - Price of Oral Capsule, Extended Release of Dosage 68.5 mg (US$), March' 2020
• Figure 10-3: Gocovri - Price of Oral Capsule, Extended Release of Dosage 137 mg (US$), March' 2020
• Figure 10-4: Global - Gocovri Quarterly Sales Q1 - Q4 (US$ Million), 2019
• Figure 10-5: Global - Gocovri Annual Sales (US$ Million), 2018 & 2019
• Figure 10-6: Osmolex ER - Available Dosage Strengths (mg), March' 2020
• Figure 10-7: Osmolex ER - Price of Oral Capsules, Extended Release 129 mg (US$), March' 2020
• Figure 10-8: Osmolex ER - Price of Oral Capsules, Extended Release 193 mg (US$), March' 2020
• Figure 10-9: Osmolex ER - Price of Oral Tablets, Extended Release 258 mg (US$), March' 2020
• Figure 10-10: Global - Selling, General & & Administrative Expenses Q1 - Q4 (US$ Million), 2018
• Figure 10-11: Global - Selling, General & & Administrative Expenses Q1 - Q4 (US$ Million), 2019
• Figure 10-12: Global - Osmolex ER Selling, General & Administrative Expenses Q1 (US$ Million), 2018 & 2019
• Figure 10-13: Global - Osmolex ER Selling, General & Administrative Expenses Q2 (US$ Million), 2018 & 2019
• Figure 10-14: Global - Osmolex ER Selling, General & Administrative Expenses Q3 (US$ Million), 2018 & 2019
• Figure 10-15: Global - Osmolex ER Q4 Selling, General & Administrative Expenses (US$ Million), 2018 & 2019
• Figure 11-1: Perseris: Available Dosage Strengths (mg)
• Figure 11-2: Perseris: Price of 1 Subcutaneous Powder for Injection, Extended Release (US$) March' 2020
• Figure 11-3: Global - Perseris Estimated Annual Sales (US$ Million), 2019 - 2025
• Figure 11-4: Invega - Available Dosage Strengths (mg)
• Figure 11-5: Invega - Price of Oral Tablets, Extended Release of Dosage 1.5 mg (US$), March' 2020
• Figure 11-6: Invega - Price of Oral Tablets, Extended Release of Dosage 3 mg (US$), March' 2020
• Figure 11-7: Invega - Price of Oral Tablets, Extended Release of Dosage 6 mg (US$), March' 2020
• Figure 11-8: Invega - Price of Oral Tablets, Extended Release of Dosage 9 mg (US$), March' 2020
• Figure 11-9: Invega Sustenna - Available Dosage Strengths (mg)
• Figure 11-10: Invega Trinza - Available Dosage Strengths (mg)
• Figure 11-11: Invega Sustenna - Price of Intramuscular Suspension, Extended Release of Dosage 39 mg (US$), March' 2020
• Figure 11-12: Invega Sustenna - Price of Intramuscular Suspension, Extended Release of Dosage 78 mg (US$), March' 2020
• Figure 11-13: Invega Sustenna - Price of Intramuscular Suspension, Extended Release of Dosage 117 mg (US$), March' 2020
• Figure 11-14: Invega Sustenna - Price of Intramuscular Suspension, Extended Release of Dosage 156 mg (US$), March' 2020
• Figure 11-15: Invega Sustenna - Price of Intramuscular Suspension, Extended Release of Dosage 234 mg (US$), March' 2020
• Figure 11-16: Invega Trinza - Price of Intramuscular Suspension Extended Release 273 mg (US$), March' 2020
• Figure 11-17: Invega Trinza - Price of Intramuscular Suspension Extended Release 410 mg (US$), March' 2020
• Figure 11-18: Invega Trinza - Price of Intramuscular Suspension Extended Release 546 mg (US$), March' 2020
• Figure 11-19: Invega Trinza - Price of Intramuscular Suspension Extended Release 819 mg (US$), March' 2020
• Figure 11-20: US - Invega Sustenna/ Invega Trinza Quarterly Sales Q1 - Q4 (US$ Million), 2018
• Figure 11-21: Global - Invega Sustenna/ Invega Trinza Quarterly Sales Q1 - Q4 (US$ Million), 2018
• Figure 11-22: Global - Invega Sustenna/ Invega Trinza Regional Sales Q1 - Q4 (US$ Million), 2018
• Figure 11-23: US - Invega Sustenna/ Invega Trinza Regional Sales Q1 - Q4 (US$ Million), 2019
• Figure 11-24: Global - Invega Sustenna/ Invega Trinza Sales Q1 - Q4 (US$ Million), 2019
• Figure 11-25: Global - Invega Sustenna/ Invega Trinza Regional Sales Q1 - Q4 (US$ Million), 2019
• Figure 11-26: Seroquel XR - Available Dosage Strengths (mg)
• Figure 11-27: Seroquel XR - Price of Oral Tablets, Extended Release of Dosage 50 mg (US$), March' 2020
• Figure 11-28: Seroquel XR - Price of Oral Tablets, Extended Release of Dosage 150 mg (US$), March' 2020
• Figure 11-29: Seroquel XR - Price of Oral Tablets, Extended Release of Dosage 200 mg (US$), March' 2020
• Figure 11-30: Seroquel XR - Price of Oral Tablets, Extended Release of Dosage 300 mg (US$), March' 2020
• Figure 11-31: Seroquel XR - Price of Oral Tablets, Extended Release of Dosage 300 mg (US$), March' 2020
• Figure 11-32: Global - Seroquel XR Total Annual Sales (US$ Million), 2017 - 2019
• Figure 11-33: Global - Seroquel XR Quarterly Sales Q1 - Q4 (US$ Million), 2018
• Figure 11-34: Global - Seroquel XR Quarterly Sales Q1 - Q4 (US$ Million), 2019
• Figure 11-35: Abilify Maintena - Available Dosage Strengths (mg)
• Figure 11-36: Abilify Maintena - Price of Intramuscular Powder for Injection, Extended Release for Dosage 300 mg & 400 mg (US$), March' 2020
• Figure 11-37: Global - Abilify Maintena Quarterly Sales Q1 - Q4 (US$ Million), 2018
• Figure 11-38: Global - Abilify Maintena Quarterly Sales Q1 - Q3 (US$ Million), 2019
• Figure 11-39: North America - Abilify Maintena Quarterly Sales Q1 - Q4 (US$ Million), 2018 & 2019
• Figure 11-40: Aristada - Available Dosage Strengths (mg)
• Figure 11-41: Aristada - Price of Intramuscular Suspension, Extended Release of Dosage 441 mg (US$), March' 2020
• Figure 11-42: Aristada - Price of Intramuscular Suspension, Extended Release of Dosage 662 mg (US$), March' 2020
• Figure 11-43: Aristada - Price of Intramuscular Suspension, Extended Release of Dosage 882 mg (US$), March' 2020
• Figure 11-44: Aristada - Price of Intramuscular Suspension, Extended Release of Dosage 1064 mg (US$), March' 2020
• Figure 11-45: Global - Aristada Quarterly Sales Q1-Q4 (US$ Million), 2018
• Figure 11-46: Global - Aristada Quarterly Sales Q1-Q4 (US$ Million), 2019
• Figure 12-1: Zohydro ER - Available Dosage Strengths (mg)
• Figure 12-2: Zohydro ER - Price of Oral Capsules, Extended Release of Dosage 10 mg (US$), 2020
• Figure 12-3: Zohydro ER - Price of Oral Capsules, Extended Release of Dosage 15 mg (US$), 2020
• Figure 12-4: Zohydro ER - Price of Oral Capsules, Extended Release of Dosage 20 mg (US$), 2020
• Figure 12-5: Zohydro ER - Price of Oral Capsules, Extended Release of Dosage 30 mg (US$), 2020
• Figure 12-6: Zohydro ER - Price of Oral Capsules, Extended Release of Dosage 40 mg (US$), 2020
• Figure 12-7: Zohydro ER - Price of Oral Capsules, Extended Release of Dosage 50 mg (US$), 2020
• Figure 12-8: Global - Zohydro ER Quarterly Sales Q1 - Q4 (US$ Million), 2018
• Figure 12-9: Hysingla ER - Available Dosage Strengths (mg)
• Figure 12-10: Hysingla ER - Price of Oral Tablet, Extended Release of Dosage 20 mg (US$), 2020
• Figure 12-11: Hysingla ER - Price of Oral Tablet, Extended Release of Dosage 30 mg (US$), 2020
• Figure 12-12: Hysingla ER - Price of Oral Tablet, Extended Release of Dosage 40 mg (US$), 2020
• Figure 12-13: Hysingla ER - Price of Oral Tablet, Extended Release of Dosage 60 mg (US$), 2020
• Figure 12-14: Hysingla ER - Price of Oral Tablet, Extended Release of Dosage 80 mg (US$), 2020
• Figure 12-15: Hysingla ER - Price of Oral Tablet, Extended Release of Dosage 100 mg (US$), 2020
• Figure 12-16: Hysingla ER - Price of Oral Tablet, Extended Release of Dosage 120 mg (US$), 2020
• Figure 12-17: Nucynta ER - Available Dosage Strengths (mg)
• Figure 12-18: Global - Price of Nucynta ER Oral Tablets, Extended Release of Dosage 50 mg (US$), 2020
• Figure 12-19: Global - Price of Nucynta ER Oral Tablets, Extended Release of Dosage 100 mg (US$), 2020
• Figure 12-20: Global - Price of Nucynta ER Oral Tablets, Extended Release of Dosage 150 mg (US$), 2020
• Figure 12-21: Global - Price of Nucynta ER Oral Tablets, Extended Release of Dosage 200 mg (US$), 2020
• Figure 12-22: Global - Price of Nucynta ER Oral Tablets, Extended Release of Dosage 250 mg (US$), 2020
• Figure 12-23: Global - Nucynta ER Annual Sales (US$ Million), 2018 & 2019
• Figure 12-24: Global - Nucynta ER Quarterly Sales Q1 - Q4 (US$ Million), 2018
• Figure 12-25: Global - Nucynta ER Quarterly Sales Q1 - Q4 (US$ Million), 2019
• Figure 12-26: Kadian - Available Dosage Strengths (mg)
• Figure 12-27: Kadian - Price of Oral Capsules, Extended Release of Dosage 10 mg/12 to 24 hr (US$), 2020
• Figure 12-28: Kadian - Price of Oral Capsules, Extended Release of Dosage 20 mg/12 to 24 hr (US$), 2020
• Figure 12-29: Kadian - Price of Oral Capsules, Extended Release of Dosage 30 mg/12 to 24 hr (US$), 2020
• Figure 12-30: Kadian - Price of Oral Capsules, Extended Release of Dosage 40 mg/12 to 24 hr (US$), 2020
• Figure 12-31: Kadian - Price of Oral Capsules, Extended Release of Dosage 50 mg/12 to 24 hr (US$), 2020
• Figure 12-32: Kadian - Price of Oral Capsules, Extended Release of Dosage 60 mg/12 to 24 hr (US$), 2020
• Figure 12-33: Kadian - Price of Oral Capsules, Extended Release of Dosage 80 mg/12 to 24 hr (US$), 2020
• Figure 12-34: Kadian - Price of Oral Capsules, Extended Release of Dosage 100 mg/12 to 24 hr (US$), 2020
• Figure 12-35: Kadian - Price of Oral Capsules, Extended Release of Dosage 200 mg/12 to 24 hr (US$), 2020
• Figure 12-36: Arymo ER - Available Dosage Strengths (mg)
• Figure 12-37: Global - Price of Arymo ER Oral Tablets, Extended Release of Dosage 15 mg/8 to 12 hr (US$), 2020
• Figure 12-38: Global - Price of Arymo ER Oral Tablets, Extended Release of Dosage 30 mg/8 to 12 hr (US$), 2020
• Figure 12-39: Global - Price of Arymo ER Oral Tablets, Extended Release of Dosage 60 mg/8 to 12 hr (US$), 2020
• Figure 12-40: Global - Arymo ER Quarterly Sales Q2 & Q3 (US$ Million), 2018
• Figure 12-41: Xtampza ER - Available Dosage Strengths (mg)
• Figure 12-42: Global - Price of Xtampza ER Oral Capsules, Extended Release of Dosage 9 mg (US$), 2020
• Figure 12-43: Global - Price of Xtampza ER Oral Capsules, Extended Release of Dosage 13.5 mg (US$), 2020
• Figure 12-44: Global - Price of Xtampza ER Oral Capsules, Extended Release of Dosage 18 mg (US$), 2020
• Figure 12-45: Global - Price of Xtampza ER Oral Capsules, Extended Release of Dosage 27 mg (US$), 2020
• Figure 12-46: Global - Price of Xtampza ER Oral Capsules, Extended Release of Dosage 36 mg (US$), 2020
• Figure 12-47: Global - Xtampza ER Quarterly Sales Q1 - Q4 (US$ Million), 2018
• Figure 12-48: Global - Xtampza ER Quarterly Sales Q1 - Q4 (US$ Million), 2019
• Figure 12-49: MS Contin - Available Dosage Strengths (mg)
• Figure 12-50: Global - Price of MS Contin Oral Tablet, Extended Release of Dosage 15 mg/ 8 to 12 hr (US$), 2020
• Figure 12-51: Global - Price of MS Contin Oral Tablet, Extended Release of Dosage 30 mg/ 8 to 12 hr (US$), 2020
• Figure 12-52: Global - Price of MS Contin Oral Tablet, Extended Release of Dosage 60 mg/ 8 to 12 hr (US$), 2020
• Figure 12-53: Global - Price of MS Contin Oral Tablet, Extended Release of Dosage 100 mg/ 8 to 12 hr (US$), 2020
• Figure 12-54: Global - Price of MS Contin Oral Tablet, Extended Release of Dosage 200 mg/ 8 to 12 hr (US$), 2020
• Figure 12-55: Global - Price of Embeda Oral Capsules, Extended Release of Dosage 20 mg - 0.8 mg (US$), 2020
• Figure 12-56: Global - Price of Embeda Oral Capsules, Extended Release of Dosage 30 mg - 1.2mg (US$), 2020
• Figure 12-57: Global - Price of Embeda Oral Capsules, Extended Release of Dosage 50 mg - 2mg (US$), 2020
• Figure 12-58: Global - Price of Embeda Oral Capsules, Extended Release of Dosage 60 mg - 2.4 mg (US$), 2020
• Figure 12-59: Global - Price of Embeda Oral Capsules, Extended Release of Dosage 80 mg - 3.2mg (US$), 2020
• Figure 12-60: Global - Price of Embeda Oral Capsules, Extended Release of Dosage 100 mg - 4 mg (US$), 2020
• Figure 13-1: Ampyra - Price of Oral Tablet, Extended Release of Dosage 10 mg (US$), 2020
• Figure 13-2: Global - Ampyra Quarterly Sales Q1 - Q4 (US$ Million), 2018
• Figure 13-3: Global - Ampyra Quarterly Sales Q1 - Q4 (US$ Million), 2019
• Figure 13-4: Global - Ampyra Total Sales (US$ Million), 2018 & 2019
• Figure 13-5: Tecfidera - Available Dosage Strengths (mg)
• Figure 13-6: Tecfidera - Price of Oral Capsule, Delayed Release of Dosage 120 mg (US$), 2020
• Figure 13-7: Tecfidera - Price of Oral Capsule, Delayed Release of Dosage 240 mg (US$), 2020
• Figure 13-8: Global - Tecdifera Quarterly Sales Q1 - Q4 (US$ Million), 2018
• Figure 13-9: Global - Tecdifera Quarterly Sales Q1 - Q3 (US$ Million), 2019
• Figure 13-10: US - Tecdifera Quarterly Sales Q1 - Q3 (US$ Million), 2018 & 2019
• Figure 13-11: Rayos - Available Dosage Strengths (mg)
• Figure 13-12: Rayos - Price of Oral Tablet, Delayed Release of Dosage 1 mg (US$), 2020
• Figure 13-13: Rayos - Price of Oral Tablet, Delayed Release of Dosage 2 mg (US$), 2020
• Figure 13-14: Rayos - Price of Oral Tablet, Delayed Release of Dosage 5 mg (US$), 2020
• Figure 13-15: Global - Rayos Quarterly Sales Q1 - Q4 (US$ Million), 2018
• Figure 13-16: Global - Rayos Quarterly Sales Q1 - Q4 (US$ Million 2019
• Figure 13-17: Vumerity - Price of 231 mg Bottle, Delayed Release (US$), 2020
• Figure 13-18: Global - Vumerity Fourth Quarter Sales Q4 (US$ Million), 2019
• Figure 14-1: Glumetza - Available Dosage Strengths (mg)
• Figure 14-2: Global - Price of Glumetza Oral Tablets, Extended Release of Dosage 500 mg (US$), 2020
• Figure 14-3: Global - Price of Glumetza Oral Tablets, Extended Release of Dosage 1000 mg (US$), 2020
• Figure 14-4: Glucotrol XL - Available Dosage Strengths (mg)
• Figure 14-5: Global - Price of Glucotrol XL Oral Tablets Extended Release of Dosage 2.5 mg (US$), 2020
• Figure 14-6: Global - Price of Glucotrol XL Oral Tablets Extended Release of Dosage 5 mg (US$), 2020
• Figure 14-7: Global - Price of Glucotrol XL Oral Tablets Extended Release of Dosage 5 mg (US$), 2020
• Figure 14-8: Global - Price of Glucotrol XL Oral Tablets Extended Release of Dosage 10 mg (US$), 2020
• Figure 14-9: Global - Price of Glucotrol XL Oral Tablets Extended Release of Dosage 10 mg (US$), 2020
• Figure 14-10: Fortamet - Available Dosage Strengths (mg)
• Figure 14-11: Global - Price of Fortamet Oral Tablets, Extended Release of Dosage 500 mg (US$), 2020
• Figure 14-12: Global - Price of Fortamet Oral Tablets, Extended Release of Dosage 1000 mg (US$), 2020
• Figure 14-13: Glucophage XR - Available Dosage Strengths (mg)
• Figure 14-14: Global - Price of Glucophage XR Oral Tablet, Extended Release of Dosage 500 mg (US$), 2020
• Figure 14-15: Global - Price of Glucophage XR Oral Tablet, Extended Release of Dosage 750 mg (US$), 2020
• Figure 14-16: Global - Price of Bydureon Powder for Injection of Dosage 2mg (US$), 2020
• Figure 14-17: Global - Bydureon Quarterly Sales Q1 - Q4 (US$ Million), 2018
• Figure 14-18: Global - Bydureon Quarterly Sales Q1 - Q4 (US$ Million), 2019
• Figure 15-1: Procardia XL - Available Dosage Strengths (mg)
• Figure 15-2: Global - Price of Procardia XL Oral Tablet, Extended Release of Dosage 30 mg (US$), 2020
• Figure 15-3: Global - Price of Procardia XL Oral Tablet, Extended Release of Dosage 30 mg (US$), 2020
• Figure 15-4: Global - Price of Procardia XL Oral Tablet, Extended Release of Dosage 60 mg (US$), 2020
• Figure 15-5: Global - Price of Procardia XL Oral Tablet, Extended Release of Dosage 60 mg (US$), 2020
• Figure 15-6: Global - Price of Procardia XL Oral Tablet, Extended Release of Dosage 90 mg (US$), 2020
• Figure 15-7: Toprol XL - Available Dosage Strengths
• Figure 15-8: Global - Price of Toprol XL Oral Tablet, Extended Release of Dosage 25 mg (US$), 2020
• Figure 15-9: Global - Price of Toprol XL Oral Tablet, Extended Release of Dosage 25 mg (US$), 2020
• Figure 15-10: Global - Price of Toprol XL Oral Tablet, Extended Release of Dosage 50 mg (US$), 2020
• Figure 15-11: Global - Price of Toprol XL Oral Tablet, Extended Release of Dosage 50 mg (US$), 2020
• Figure 15-12: Global - Price of Toprol XL Oral Tablet, Extended Release of Dosage 100 mg (US$), 2020
• Figure 15-13: Global - Price of Toprol XL Oral Tablet, Extended Release of Dosage 100 mg (US$), 2020
• Figure 15-14: Global - Price of Toprol XL Oral Tablet, Extended Release of Dosage 200 mg (US$), 2020
• Figure 15-15: Global - Price of Toprol XL Oral Tablet, Extended Release of Dosage 200 mg (US$), 2020
• Figure 15-16: Adalat CC - Available Dosage Strengths (mg)
• Figure 15-17: Global - Price of Adalat CC Oral Tablet Extended Release of Dosage 30 mg (US$), 2020
• Figure 15-18: Global - Price of Adalat CC Oral Tablet Extended Release of Dosage 30 mg (US$), 2020
• Figure 15-19: Global - Price of Adalat CC Oral Tablet Extended Release of Dosage 60 mg (US$), 2020
• Figure 15-20: Global - Price of Adalat CC Oral Tablet Extended Release of Dosage 60 mg (US$), 2020
• Figure 15-21: Global - Price of Adalat CC Oral Tablet Extended Release of Dosage 90 mg (US$), 2020
• Figure 15-22: Verelan PM - Available Dosage Strengths (mg)
• Figure 15-23: Global - Price of Verelan PM Oral Capsule, Extended Release of Dosage 200 mg/24 hr (US$), 2020
• Figure 15-24: Global - Price of Verelan PM Oral Capsule, Extended Release of Dosage 300 mg/24 hr (US$), 2020
• Figure 15-25: Plendil - Available Dosage Strengths (mg)
• Figure 15-26: Global - Price of Plendil Oral Tablet, Extended Release of Dosage 2.5 mg (US$), 2020
• Figure 15-27: Global - Price of Plendil Oral Tablet, Extended Release of Dosage 5 mg (US$), 2020
• Figure 15-28: Global - Price of Plendil Oral Tablet, Extended Release of Dosage 10 mg (US$), 2020
• Figure 15-29: Cardizem LA - Available Dosage Strengths (mg)
• Figure 15-30: Global - Price of Cardizem LA Oral Tablet, Extended Release of Dosage 120 mg/24 hr (US$), 2020
• Figure 15-31: Global - Price of Cardizem LA Oral Tablet, Extended Release of Dosage 120 mg/24 hr (US$), 2020
• Figure 15-32: Global - Price of Cardizem LA Oral Tablet, Extended Release of Dosage 180 mg/24 hr (US$), 2020
• Figure 15-33: Global - Price of Cardizem LA Oral Tablet, Extended Release of Dosage 180 mg/24 hr (US$), 2020
• Figure 15-34: Global - Price of Cardizem LA Oral Tablet, Extended Release of Dosage 240 mg/24 hr (US$), 2020
• Figure 15-35: Global - Price of Cardizem LA Oral Tablet, Extended Release of Dosage 240 mg/24 hr (US$), 2020
• Figure 15-36: Global - Price of Cardizem LA Oral Tablet, Extended Release of Dosage 300 mg/24 hr (US$), 2020
• Figure 15-37: Global - Price of Cardizem LA Oral Tablet, Extended Release of Dosage 300 mg/24 hr (US$), 2020
• Figure 15-38: Global - Price of Cardizem LA Oral Tablet, Extended Release of Dosage 360 mg/24 hr (US$), 2020
• Figure 15-39: Global - Price of Cardizem LA Oral Tablet, Extended Release of Dosage 360 mg/24 hr (US$), 2020
• Figure 15-40: Global - Price of Cardizem LA Oral Tablet, Extended Release of Dosage 420 mg/24 hr (US$), 2020
• Figure 15-41: Global - Price of Cardizem LA Oral Tablet, Extended Release of Dosage 420 mg/24 hr (US$), 2020
• Figure 18-1: US -Controlled Release Market Size (US$ Billion), 2019 - 2026
• Figure 18-2: US - Population Above & Below 65 Years of Age (%), 2018
• Figure 18-3: US - Share in Global Controlled Release Drug Market (%), 2019
• Figure 18-4: Europe -Controlled Release Drug Delivery Market Size (US$ Billion), 2019 - 2026
• Figure 18-5: Europe - Share in Global Controlled Release Drug Market (%), 2019
• Figure 18-6: European Union - Population Above & Below 65 Years (%), 2018
• Figure 18-7: European Union - Estimated Cases of Dementia, 2030 & 2050
• Figure 18-8: Japan - Population Above & Below 65 Years (%), 2019
• Figure 18-9: Japan - Dementia Cases (Million), 2018 & 2025
• Figure 19-1: Accelerative Parameters of Controlled Drug Delivery Systems
• Figure 19-2: Major Challenges Faced by Controlled Drug Delivery System
• Figure 20-1: Global - Controlled Release Drug Delivery Market Size (US$ Billion), 2019 - 2026

"Global Controlled Release Drug Delivery Market, Drug Dosage, Price & Clinical Trial Insight 2026" Report Highlights:

• Global Controlled Release Drug Delivery Market: More Than US$ 70 Billion Opportunity by 2026

• US & Europe Market Share 2019: > 65%

• US & Europe To Double It Market Sales Opportunity by 2026

• Number of Controlled Release Drug Available in Market: > 140 Drugs

• Clinical Trials Insight by Company, Country, Indication & Patent: > 250 Drugs

• Controlled Release Drugs Pricing, Patent & Dosage Insight

• Global & Regional Trend Analysis, Future Market Opportunity Outlook

• Global Controlled Drug Delivery Market Dynamics

The market established for the target patient segment focuses towards delivering drugs at a predetermined rate, systemically or locally for a specific period of time. Although the market is predominated by regular drugs but the continuous delivery of the drugs whose kinetics can be controlled is achieving a predictable growth curve. The market utilizes drug encapsulating devices which employ controlled release of the therapeutic agents ranging from days to months. The numerous advantages provided by market over traditional methods of drug delivery such as tailoring of rate of drug release, fragile drug protection and patient comfort and compliance is what changing the prescription pattern of the doctors towards controlled release drugs.

Extensions supplied to the available drug market in terms of mechanical strength, increasing demand of the patient population and novel drugs capable of achieving high drug loading are some of the factors that are considered as major driving factors for the controlled release drug delivery market. Other than the above mentioned factors, the market is coupled with reduced drug toxicity which is however estimated to boost the market growth in a short period of time.

In the last few years, increasing efforts have been delivered in order to diversify the range of the drug delivery and this has been processed by increasing the association of the researchers with the daily and unmet needs of the patient population. The availability of the controlled release drug delivery system in the market has shown a great progress towards handling the situation of the complex real world as the emergence of drugs that could not regulate the complex composition of disease was hampering with the overall growth of the drug market.

The availability of controlled release drugs in oral, injectable, nasal, topical and implantable forms for the patient population is making the market more dominant than the other available markets. The emergence of the market ended the search for the novel solutions to address the therapeutics challenges as well as has provided a great concern in the biotechnology and pharmaceutical industries. The amazing perspective lined up the way of controlled released drug market represents a more personalized and efficient delivery system in the coming years.

Although the platform that has been provided by the controlled release drug delivery market is novel but the drug delivery platform provided by market has been associated with impressive clinical pipeline. It carries the potential to treat a broad spectrum of disease such as infectious diseases, inflammatory diseases, autoimmune diseases, neurological diseases and several different types of cancer. The market is capable of offering a revolutionized treatment for the patients in order to truly modify the benefits that the patients were receiving from a long period of time.

According to the research conducted by the team, it is estimated that the market is availing safe and effective pharmacotherapeutic treatment regimen for the patient population that are in an urgent need of the drug delivery system capable of transforming their treatment schedule. Although the market is associated with significant challenges for the scientists and clinicians but the availability of technological drivers will be responsible for rapid discovery of drugs related to the market. The formulation changes and safety specifications coupled with the market is estimated to encourage the people towards its consumption. The optimistic landscape of the market guarantees the complete success of the market as well as a major competition for the drugs in the near future.

Table of Contents

1. Introduction to Drug Delivery Methodology

• 1.1 Drug Delivery Overview
• 1.2 Drug Delivery System

2. Introduction to Controlled Drug Delivery

• 2.1 Novel Drug Delivery Systems
• 2.2 Preamble to Controlled Drug Delivery
• 2.3 Drug Delivery Technology
  • 2.3.1 First Generation
  • 2.3.2 Second Generation
• 2.4 Fundamentals of Controlled Delivery
• 2.5 Basis for Controlled Drug Delivery

3. Controlled Drug Delivery Classification

• 3.1 By Delivery Systems
  • 3.1.1 Immediate Drug Release System
  • 3.1.2 Modified Drug Release System
  • 3.1.3 Delayed Release System
  • 3.1.4 Extended Release System
  • 3.1.5 Pulsatile Drug Release System
• 3.2 By Technology
  • 3.2.1 Rate Preprogrammed Drug Delivery System
  • 3.2.2 Activation Modulated Drug Delivery System
  • 3.2.3 Feed Back Regulated Drug Delivery System
  • 3.2.4 Site Targeted Drug Delivery Systems
• 3.3 By Routes of Delivery
  • 3.3.1 Oral Controlled Drug Delivery System
  • 3.3.2 Nasal Controlled Drug Delivery System
  • 3.3.3 Transdermal Controlled Drug Delivery System
  • 3.3.4 Ocular Controlled Drug Delivery System
  • 3.3.5 Parenteral Controlled Drug Delivery

4. Controlled Drug Delivery Mechanism of Action

• 4.1 Diffusion Controlled
• 4.2 Dissolution Controlled System
• 4.3 Water Penetration Controlled System
• 4.4 Erosion Controlled System
• 4.5 Ion-Exchange Controlled System

5. Material Based Approaches for Controlled Drug Delivery

• 5.1 Polymers
• 5.2 Chronopharmaceutics
• 5.3 Nanoparticulate Delivery System

6. Global Controlled Release Drug Clinical Pipeline Overview

• 6.1 Phase
• 6.2 Country/Region
• 6.3 Mode of Action
• 6.4 Drug class
• 6.5 Indication

7. Controlled Drug Delivery by Indication

• 7.1 Diabetes
• 7.2 Cancer
• 7.3 Cardiovascular Diseases
• 7.4 Neurological Disorders
• 7.5 Infections

8. Controlled Delivery Drug Dosage & Formulation Insight

• 8.1 Enteral Dosage Formulations
  • 8.1.1 Solid Dosage Forms
  • 8.1.2 Liquid Dosage Forms
  • 8.1.3 Inhalation Dosage Forms
• 8.2 Parenteral Dosage Forms
  • 8.2.1 Injectable Dosage Forms
  • 8.2.2 Implantable Device
• 8.3 General Mechanisms of Drug Release

9. Controlled Release Drugs for Alzheimer's Disease - Pricing, Patent & Dosage Insight

• 9.1 Namzaric (Extended-Release)
• 9.2 Namenda XR (Extended - Release)
• 9.3 Razadyne ER (Extended - Release)

10. Controlled Release Drugs for Parkinson's Disease - Pricing, Patent & Dosage Insight

• 10.1 Gocovri (Extended- Release)
• 10.2 Osmolex ER (Extended - Release)

11. Controlled Release Drugs for Schizophrenia - Pricing, Patent & Dosage Insight

• 11.1 Perseris (Extended - Release)
• 11.2 Invega (Extended - Release)
• 11.3 Invega Sustenna/Invega Trinza (Extended - Release)
• 11.4 Seroquel XR (Extended - Release)
• 11.5 Abilify Maintena (Extended - Release)
• 11.6 Aristada (Extended - Release)

12. Controlled Release Drugs for Chronic Pain - Pricing, Patent & Dosage Insight

• 12.1 Zohydro ER (Extended - Release)
• 12.2 Hysingla ER (Extended - Release)
• 12.3 Nucynta ER (Extended - Release)
• 12.4 Kadian (Extended - Release)
• 12.5 Arymo ER (Extended - Release)
• 12.6 Xtampza ER (Extended - Release)
• 12.7 MS Contin (Extended - Release)
• 12.8 Embeda (Extended - Release)

13. Controlled Release Drugs for Multiple Sclerosis - Pricing, Patent & Dosage Insight

• 13.1 Ampyra (Extended - Release)
• 13.2 Tecfidera (Delayed - Release)
• 13.3 Rayos (Delayed - Release)
• 13.4 Vumerity (Delayed - Release)

14. Controlled Release Drugs for Diabetes Mellitus Type II - Pricing, Patent & Dosage Insight

• 14.1 Glumetza (Extended - Release)
• 14.2 Glucotrol XL (Extended - Release)
• 14.3 Fortamet (Extended - Release)
• 14.4 Glucophage XR (Extended - Release)
• 14.5 Bydureon (Extended - Release)

15. Controlled Release Drugs for Hypertension & Angina Pectoris - Pricing, Patent & Dosage Insight

• 15.1 Procardia XL (Extended - Release)
• 15.2 Toprol XL (Extended - Release)
• 15.3 Adalat CC (Extended - Release)
• 15.4 Verelan PM (Extended - Release)
• 15.5 Plendil (Extended - Release)
• 15.6 Cardizem LA (Extended - Release)

16. Global Controlled Drug Clinical Trials Insight By Company, Indication & Phase

• 16.1 Unknown
• 16.2 Research
• 16.3 Preclinical
• 16.4 Clinical
• 16.5 Phase-I
• 16.6 Phase-I/II
• 16.7 Phase-II
• 16.8 Phase-II/III
• 16.9 Phase-III
• 16.10 Preregistration
• 16.11 Registered

17. Marketed Controlled Drug Clinical Insight By Company & Indication

18. Global Controlled Drug Market Overview & Recent Trends at Regional Level

• 18.1 US
• 18.2 Europe
• 18.3 Japan

19. Global Controlled Drug Delivery Market Dynamics

• 19.1 Market Drivers
• 19.2 Challenges to be Resolved

20. Global Controlled Drug Delivery Market Future Outlook

21. Competitive Landscape

• 21.1 Allergan
• 21.2 Amylin Pharmaceuticals
• 21.3 AstraZeneca
• 21.4 BioAlliance Pharma
• 21.5 Biogen
• 21.6 Collegium Pharmaceutical
• 21.7 Controlled Therapeutics (Ferring Pharmaceuticals)
• 21.8 Cosmo Pharmaceuticals
• 21.9 Egalet
• 21.10 Elan Corporation
• 21.11 Encore Therapeutics
• 21.12 Flamel Technologies
• 21.13 GlaxoSmithKline
• 21.14 Heron Therapeutics
• 21.15 iCeutica
• 21.16 Mithra Pharmaceuticals
• 21.17 Neurim Pharmaceuticals
• 21.18 Novartis
• 21.19 Orexigen Therapeutics
• 21.20 Otsuka Pharmaceutical
• 21.21 Pfizer
• 21.22 Purdue Pharma
• 21.23 Syntex Pharmaceuticals International
• 21.24 Takeda
• 21.25 Zealand Pharma